A Phase 2 Trial of Temsirolimus and Bevacizumab in Patients With Endometrial, Ovarian, Hepatocellular Carcinoma, Carcinoid or Islet Cell Cancer

Trial Profile

A Phase 2 Trial of Temsirolimus and Bevacizumab in Patients With Endometrial, Ovarian, Hepatocellular Carcinoma, Carcinoid or Islet Cell Cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 13 Jul 2017

At a glance

  • Drugs Bevacizumab (Primary) ; Temsirolimus (Primary)
  • Indications Adenocarcinoma; Adenoma; Carcinoid tumour; Endometrial cancer; Fallopian tube cancer; Liver cancer; Neuroendocrine carcinoma; Ovarian cancer; Pancreatic cancer; Peritoneal cancer; Uterine cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 Jul 2017 Status changed from active, no longer recruiting to completed.
    • 09 Mar 2017 Planned primary completion date changed from 1 Jun 2016 to 1 Sep 2017.
    • 22 Feb 2016 Planned primary completion date changed from 1 Feb 2016 to 1 Jun 2016 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top